Pharmacometrics in psychiatric diseases

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 14, Issue , 2014, Pages 407-449

  de Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; DESVENLAFAXINE; DIAZEPAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LORAZEPAM; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NORTRIPTYLINE; OXAZEPAM; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SERTRALINE; TRANYLCYPROMINE; TRIMIPRAMINE; VENLAFAXINE;

ABDOMINAL CRAMP; ACUTE STRESS DISORDER; ALLERGIC REACTION; AMNESIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DEPENDENCE; ELECTROENCEPHALOGRAM; FAINTNESS; FATIGUE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; MAJOR DEPRESSION; MATHEMATICAL MODEL; MENTAL DISEASE; META ANALYSIS (TOPIC); NAUSEA; NAUSEA AND VOMITING; NERVE CELL INHIBITION; PANIC; PHARMACOMETRICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SOMNOLENCE; SYSTEMATIC REVIEW (TOPIC); WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 85033232060     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1304-6_14     Document Type: Article

References (122)

1. Agarwal N, Port JD, Bazzocchi M, Renshaw PF (2010) Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 255(1):23–41
2. Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schüttler J (1999) The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 65(6):630–639
3. Alhaj H, Wisniewski G, McAllister-Williams RH (2011) The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants. J Psychopharmacol 25(9):1175–1191
4. Alphs L, Fabrizio Benedetti F, Fleischhacker WW, Kane JM (2012) Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol 15(7):1003–1014
5. Andreasen NC, Olsen S (1982) Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39(7):789–794
6. Baghdady NT, Banik S, Swartz SA, McIntyre RS (2009) Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 26(4):404–424
7. Barbanoj MJ, Riba J, Morte A, Antonijoan RM, Janι F (2002a) Basics of PK-PD using QEEG: acute/repetitive administration, interactions. Focus on anxiolytics with different neurochemical mechanisms as examples. Methods Find Exp Clin Pharmacol 24(Suppl C):67–83
8. Barbanoj MJ, Valle M, Kulisevsky J, Pιrez V, Gambϊs P (2002b) Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario. Methods Find Exp Clin Pharmacol 24(Suppl D):139–144
9. Baumann P (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31(6):444–469
10. Ben Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocrin Rev 22:724–763
11. Ben Jonathan N, LaPensee CR, LaPensee EW (2008) What can we learn from rodents about prolactin in humans? Endocrin Rev 29:1–41
12. Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, Bogerts B (2010) The hypothalamus in schizophrenia research: no longer a wallflower existence. Open Neuroendocrinol J 3:59–67
13. Bigos KL, Pollock BG, Stankevich BA, Bies RR (2009) Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med 6(4):522–543
14. Bishop SJ (2007) Neurocognitive mechanisms of anxiety: an integrative account. Trends Cogn Sci 11(7):307–316
15. Cleton A, Mazee D, Voskuyl RA, Danhof M (1999) Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Br J Pharmacol 127(1):227–235
16. Cloos JM, Ferreira V (2009) Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 22(1):90–95
17. Cusack B, Nelson A, Richelson E (1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berlin) 114(4):559–565
18. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G (2005) Mechanism-based pharmacokinetic- pharmacodynamic modeling-a new classification of biomarkers. Pharm Res 22:1432–1437
19. De Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, Bruggeman R, Hoogendijk WJ, Penninx BW (2012) ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. doi:10.1038/tpj.2012.16 (Epub ahead of print)
20. De Lange ECM (2013a) The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. In: Engelhardt B, Stamirovic D, de Lange EC (eds) Fluids and barriers of the CNS, theme issue “Technique and research protocols to study brain barriers in vivo, in vitro and in situ”. Fluids and Barriers CNS 10:12
21. De Lange ECM (2013b) Utility of cerebrospinal fluid in translational neuroscience. J Pharmacokinet Pharmacodyn. (In: Bonate P (ed) Special issue “Translational modeling in neuroscience”). 40(3):315–326
22. De Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55(1):39–50
23. Delgado MR, Olsson A, Phelps EA (2006) Extending animal models of fear conditioning to humans. Biol Psychol 73(1):39–48
24. Della Pasqua O, Santen GW, Danhof M (2010) The missing link between clinical endpoints and drug targets in depression. Trends Pharmacol Sci 31(4):144–152
25. Détári L, Szentgyörgyi V, Hajnik T, Szénási G, Gacsályi I, Kukorelli T (1999) Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats. Psychopharmacology 142(3):318–326
26. Fahey JM, Pritchard GA, Moltke LL, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ (1998) Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. J Pharmacol Exp Ther 285(1):271–276
27. Farach FJ, Pruitt LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP (2012) Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord 26(8):833–843
28. Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF 3rd, Bies RR (2006) Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 61(5):558–569
29. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 66(5):629–639
30. Ferrier IN, Johnstone EC, Crow TJ, Rincon-Rodriguez I (1983) Anterior pituitary hormone secretion in chronic schizophrenics. Arch Gen Psychiatry 40(7):755–761
31. Figgitt DP, McClellan KJ (2000) Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 60(4):925–954
32. Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22(2Suppl):12–19
33. Fountoulakis KN, Möller HJ (2011) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14(3):405–412
34. Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–1631
35. Friberg LE, de Greef R, Kerbusch T, Karlsson MO (2009a) Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 86(1):84–91
36. Friberg LE, Vermeulen AM, Petersson KJ, Karlsson MO (2009b) An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 85(4):409–417
37. Geldof M, Freijer J, van Beijsterveldt L, Timmerman P, Ahnaou A, Drinkenburg WH, Danhof M (2007) Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. Eur J Pharm Sci 30(1):45–55
38. Geldof M, Freijer J, van Beijsterveldt L, Danhof M (2008a) Pharmacokinetic modeling of nonlinear brain distribution of fluvoxamine in the rat. Pharm Res 25(4):792–804
39. Geldof M, Freijer JI, Peletier LA, van Beijsterveldt L, Danhof M (2008b) Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex. Eur J Pharm Sci 33(3):217–229
40. Geldof M, Freijer JI, van Beijsterveldt L, Langlois X, Danhof M (2008c) Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex. Br J Pharmacol 154(6):1369–1378
41. Goldstein JM, Seidman LJ, Makris N, Ahern T, O’Brien LM, Caviness VS Jr, Kennedy DN, Faraone SV, Tsuang MT (2007) Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry 61(8):935–945
42. Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993) An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. Int Clin Psychopharmacol 8(3):167–172
43. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
44. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psych 23:56–62
45. Hedlund JL, Viewig BW (1979) The Hamilton rating scale for depression: a comprehensive review. J Oper Psychiat 10:149–165
46. Hiemke C, Härtter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85(1):11–28
47. Himmerich H, Wranik DW (2012) Choice of treatment with antidepressants: influencing factors. Curr Pharm Des 18(36):5958–5975
48. Hopewell S, Dutton S, Yu L-M, Chan A-M, Altman DG (2010) The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 340:c723
49. Huh J, Goebert D, Takeshita J, Lu BY, Kang M (2011) Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord. 2011;13(2). pii: PCC.08r00709. doi: 10.4088/PCC.08r00709blu.
50. Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, Pollock BG, Mulsant BH, Bies RR (2012) Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry 20(1):53–60
51. Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR (2010) Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 50(1):73–80
52. Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT (2002) Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic- pharmacodynamic analysis. Br J Anaesth 89(3):428–437
53. Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2011) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 28(10):2490–2504
54. Jonker DM, Vermeij DA, Edelbroek PM, Voskuyl RA, Piotrovsky VK, Danhof M (2003) Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. Epilepsia 44(3):329–338
55. Kay SR, Flszbein A, Opfer LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 13(2):261–276
56. Kirsch I (2009) Antidepressants and the placebo response. Epidemiol Psichiatr Soc 18(4):318–322
57. Klomp A, Tremoleda JL, Schrantee A, Gsell W, Reneman L (2012) The use of pharmacologicalchallenge fMRI in pre-clinical research: application to the 5-HT system. J Vis Exp pii:3956
58. Klotz U (1998) Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther 36(11):581–585
59. Kodish I, Rockhill C, Varley C (2011) Pharmacotherapy for anxiety disorders in children and adolescents. Dialogues Clin Neurosci 13(4):439–452
60. Koen N, Stein DJ (2011) Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 13(4):423–437
61. Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2012) Pharmacokinetic-pharmacodynamic modeling of the D2 and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res 29(7):1932–1948
62. Krijzer FNCM, Van der Molen R (1987) Classification of psychotropic drugs by rat EEG analysis: the anxiolytic profile in comparison to the antidepressant and neuroleptic profile. Neuropsychobiology 18:51–56
63. Kuperman S, Johnson B, Arndt S, Lindgren S, Wolraich M (1996) Quantitative EEG differences in a nonclinical sample of children with ADHD and undifferentiated ADD. J Am Acad Child Adolesc Psychiatry 35(8):1009–1017
64. Lader M (2008) Effectiveness of benzodiazepines: do they work or not? Expert Rev Neurother 8(8):1189–1191
65. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharmacol Ther 82(1):21–32
66. Lau CE, Wang Y, Ma F (1998) Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam. Eur J Pharmacol 346(2–3):131–144
67. Lenze EJ, Wetherell JL (2011) A lifespan view of anxiety disorders. Dialogues Clin Neurosci 13(4):381–399
68. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and metaanalysis. Lancet 379(9831):2063–2071
69. Lin JH (2007) Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3(1):81–92
70. Ma G, Friberg LE, Movin-Osswald G, Karlsson MO (2010) Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. Br J Clin Pharmacol 70(6):815–824
71. Mahmood I, Sahajwalla C (1999) Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 36(4):277–287
72. Maier W, Buller R, Philipp M, Heuser I (1988) The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14(1):61–68
73. Mandema JW, Danhof M (1992) Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 23(3):191–215
74. Mandrioli R, Mercolini L, Saracino MA, Raggi MA (2012) Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 19(12):1846–1863
75. Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron JC (2005) Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 31(5Part 1):609–615
76. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58(12):538–546
77. Matsui-Sakata A, Ohtani H, Sawada Y (2005) Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 20(3):187–199
78. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46(5):359–388
79. Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H (2012) Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry 37(1):182–187
80. Movin-Osswald G, Hammarlund-Udenaes M (1995) Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 274:921–927
81. Mucci A, Volpe U, Merlotti E, Bucci P, Galderisi S (2006) Pharmaco-EEG in psychiatry. Clin EEG Neurosci 37(2):81–98
82. Muscatello MR, Spina E, Bandelow B, Baldwin DS (2012) Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol 27(3):239–253
83. Nagayama H (1993) Chronopharmacology of psychotropic drugs: circadian rhythms in drug effects and its implications to rhythms in the brain. Pharmacol Ther 59(1):31–54
84. Nejad AB, Ebdrup BH, Glenthøj BY, Siebner HR (2012) Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics. Curr Neuropharmacol 10(3):219–230
85. Obermeier M, Schennach-Wolff R, Meyer S, Möller HJ, Riedel M, Krause D, Seemüller F (2011) Is the PANSS used correctly? a systematic review. BMC Psychiatry 11:113
86. Olkkola KT, Ahonen J (2008) Midazolam and other benzodiazepines. Handb Exp Pharmacol (182):335–360
87. Ortega I, Perez-Ruixo JJ, Stuyckens K, Piotrovsky V, Vermeulen A (2010) Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials. J Clin Pharmacol 50(3):293–310
88. Owen RT (2008) Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia. Drugs Today (Barcelona) 44(12):887–893
89. Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH (2011) Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 50(7):429–450
90. Pilla Reddy V, Kozielska M, Johnson M, Suleiman AA, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH (2012) Modelling and simulation of the positive and negative syndrome scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin Pharmacokinet 51(4):261–275
91. Pitchot W, Wauthy J, Legros JJ, Ansseau M (2004) Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study. Eur Neuropsychopharmacol 14(2):151–155
92. Prichep LS (2005) Use of normative databases and statistical methods in demonstrating clinical utility of QEEG: importance and cautions. Clin EEG Neurosci 36(2):82–87
93. Rabinowitz J, Davido O (2008a) The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 34(2):286–291
94. Rabinowitz J, Davidov O (2008b) A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medications. Schizophr Bull 34(6):1145–1150
95. Rabinowitz J, Levine SZ, Barkai O, Davidov O (2009) Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull 35(4):775–788
96. Riedel M, Strassnig M, Müller N, Zwack P, Möller HJ (2005) How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255(2):143–148
97. Rodgers RJ, Cole JC, Davies A (1994) Anti-anxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan. Pharmacol Biochem Behav 48(4):959–963
98. Sakai N, Ishizuka M (2009) Impact of rat P450 genetic polymorphism on diazepam metabolism. Expert Opin Drug Metab Toxicol 5(11):1421–1433
99. Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H (2013) Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull 39(3):564–574
100. Samtani MN, Vermeulen A, Stuyckens K (2009) Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 48(9):585–600
101. Schosser A, Kasper S (2009) The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 24(6):277–288
102. Sherwin CM, Saldaña SN, Bies RR, Aman MG, Vinks AA (2012) Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit 34(5):535–544
103. Silverman H (2007) Ethical Issues during the Conduct of Clinical Trials. Proc Am Thoracic Soc 4(2):180–184
104. Spina E, Santoro V, D’Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30(7):1206–1227
105. Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de Lange EC (2012) Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn 39(5):463–477
106. Strawn JR, Sakolsky DJ, Rynn MA (2012) Psychopharmacologic treatment of children and adolescents with anxiety disorders. Child Adolesc Psychiatr Clin N Am 21(3):527–539
107. Thyssen A, Vermeulen A, Fuseau E, Fabre MA, Mannaert E (2010) Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet 49(7):465–478
108. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC (2011) Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31:318–325
109. Van Hest A, van Drimmelen M, Olivier B (1992) Flesinoxan shows antidepressant activity in a DRL 72-s screen. Psychopharmacology 107(4):474–479
110. Vermeulen A, Piotrovsky V, Ludwig EA (2007) Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn 34(2):183–206
111. Vgontzas AN, Kales A, Bixler EO (1995) Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 51(4):205–223
112. Vinkers CH, Tijdink JK, Luykx JJ, Vis R (2012) Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics. Ned Tijdschr Geneeskd 155(35):A4900
113. Visser SA, Wolters FL, Gubbens-Stibbe JM, Tukker E, Van Der Graaf PH, Peletier LA, Danhof M (2003) Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 304(1):88–101
114. Von Wolff A, Hölzel LP, Westphal A, Härter M, Kriston L (2013) Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 144(1–2):7–15
115. Weihs K, Wert JM (2011) A primary care focus on the treatment of patients with major depressive disorder. Am J Med Sci 342(4):324–330
116. Whalley HC, Simonotto E, Flett S, Marshall I, Ebmeier KP, Owens DG, Goddard NH, Johnstone EC, Lawrie SM (2004) fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain 127(Part 3):478–490
117. Whalley HC, Whyte MC, Johnstone EC, Lawrie SM (2005) Neural correlates of enhanced genetic risk for schizophrenia. Neuroscientist 11(3):238–249
118. WHO International Consortium in Psychiatric Epidemiology (2000) Cross-national comparisons of the prevalences and correlates of mental disorders. Bull World Health Organ [online] 78(4):413–426. ISSN 0042–9686
119. Williams PJ (2007) History of phramacometrics. In: Ette EI, Williams PJ (eds) Pharmacometrics. The science of quantitative pharmacology. Whiley, New Jersey
120. Yoo HD, Cho HY, Lee SN, Yoon H, Lee YB (2012) Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J Pharmacokinet Pharmacodyn 39(4):329–341
121. Yuan R, Flockhart DA, Balian JD (1999) Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 39(11):1109–1125
122. Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M (2007) Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res 24(11):2031–2039